High Hepatic leukemia factor expression indicates a favorable survival in glioma patients

Abstract

Hepatic leukemia factor (HLF) is an oncogenic transcript factor, but its role in gliomas is unclear. With the open-access data from the Cancer Genome Atlatls (TCGA), HLF expression was compared between normal and glioma tissues and its correlation to patient survival, age, gender, race, and tumor grade was analyzed. Multivariate Cox regression was adopted to explore the independent risk factors for patient survival. Survivals between high and low HLF expression, and high and low model predicted risk subgroups were compared. 1, 2, 3, and 5-year patient survival were predicted with the Cox regression model. Gene set enrichment analysis (GSEA) was performed to predict the potential function of HLF. Expression and clinical data of 5 normal brain samples and 655 glioma samples were obtained from TCGA. HLF expression was downregulated in gliomas than normal brain tissue ( P = .007), and negatively related to patient age and advancing tumor grade ( P < .001). HLF was a protective factor for patient survival (OR = 0.81, 95%CI 0.67–0.99, P = .035). Patients’ survivals were poorer in low HLF expression subgroups and the Cox regression model predicted high-risk subgroups ( P < .001). The accuracy of the model in predicting 1, 2, 3, and 5-year patient survival was 0.864, 0.895, 0.907, and 0.893, respectively. GSEA revealed HLF mainly took part in regulating tumor cell metabolism and cell cycle. HLF was downregulated in gliomas than normal tissue, negatively related to patient age and tumor grade, and was an independent protective factor for glioma patients.

Transcriptional regulation of genetic variants in the SLC40A1 promoter

“…In childhood acute lymphocytic leukemia, E2A-HLF generated by the translocation [ 17 , 19 ] is associated with a high mortality rate [ 26 ]. Interestingly, in the case of gliomas, HLF is downregulated compared to that in the normal brain and is related to a higher survival rate [ 27 ]. Recently, we reported that HLF binds to the ATP-binding cassette subfamily 4 ( ABCA4 ) promoter and functions as an activator of ABCA4 transcription [ 28 ].…”

Developing a 5-gene prognostic signature for cervical cancer by integrating mRNA and copy number variations

“…Such a finding supported that HK2-related pathway can serve as a potential target for treating cervical cancer. Hepatic leukemia factor (HLF) is considered as an oncogenic transcript factor, and its high expression correlates with favorable prognosis in many cancers such as glioma [ 49 ] and non-small cell lung cancer [ 50 ]. This study also found that high expression of HLF was associated with a better prognosis of cervical cancer.…”

Epigenomic integrative analysis pinpoint master regulator transcription factors associated with tumorigenesis in squamous cell carcinoma of oral tongue

“…HLF encodes a member of the proline and acidic-rich (PAR) protein family, a subset of the bZIP transcription factors. In Glioma, the overexpression could inhibit proliferation and invasion, in Triple Negative Breast Cancer promotes the ferroptosis resistance in TNBC cells via GGT1 and ultimately facilitates the malignant tumor progression ( Liu Q et al , 2021 ; Li H et al , 2022 ).…”